Adagene Inc. (ADAG) Financial Ratios
7 years of historical data (2018–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
2.55
↑+122% vs avg
5yr avg: 1.14
30Y Low0.6·High1.7
ROE
↑
-55.2%
↓+39% vs avg
5yr avg: -91.1%
30Y Low-218%·High-25%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ADAG Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Adagene Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $210M | $72M | $68M | $46M | $258M | — | — | — |
| Enterprise Value | $144M | $5M | $-20015589 | $-69880897 | $91M | — | — | — |
| P/E Ratio → | -3.76 | — | — | — | — | — | — | — |
| P/S Ratio | 2037.00 | 694.63 | 3.73 | 4.94 | 25.39 | — | — | — |
| P/B Ratio | 2.55 | 1.42 | 0.96 | 0.55 | 1.65 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ADAG EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 48.32 | -1.11 | -7.52 | 8.99 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
ADAG Profitability
Margins and return-on-capital ratios measuring operating efficiency
Adagene Inc. earns an operating margin of -34835.4%. Operating margins have compressed from -903.1% to -34835.4% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -55.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -797.5% | -797.5% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -34835.4% | -34835.4% | -131.0% | -903.1% | -711.2% | -3993.7% | -3993.7% | -1147.1% |
| Net Profit Margin | -32386.4% | -32386.4% | -104.6% | -860.6% | -719.2% | -3424.1% | -3602.9% | -974.0% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | -55.2% | -55.2% | -24.7% | -66.7% | -217.9% | — | — | — |
| ROA | -32.6% | -32.6% | -14.1% | -46.8% | -53.5% | -17.3% | -21.6% | -27.0% |
| ROIC | — | — | — | — | — | — | — | — |
| ROCE | -53.1% | -53.1% | -26.1% | -65.3% | -63.5% | -23.0% | -26.9% | -39.3% |
ADAG Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $85M exceeds total debt of $18M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.37 | 0.37 | 0.32 | 0.34 | 0.05 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.32 | -1.24 | -1.39 | -1.07 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -42.20 | -42.20 | -21.41 | -121.04 | -198.93 | -94.82 | -138.81 | -190.31 |
Net cash position: cash ($85M) exceeds total debt ($18M)
ADAG Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Adagene Inc.'s current ratio of 2.30x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 2.71x to 2.30x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.30 | 2.30 | 3.61 | 2.71 | 6.24 | 4.90 | 14.47 | 5.01 |
| Quick Ratio | 2.30 | 2.30 | 3.61 | 2.71 | 6.24 | 4.90 | 14.47 | 5.01 |
| Cash Ratio | 2.23 | 2.23 | 3.49 | 2.61 | 5.85 | 4.65 | 14.00 | 4.74 |
| Asset Turnover | — | 0.00 | 0.16 | 0.06 | 0.05 | 0.01 | 0.00 | 0.03 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 29.39 | 4.47 | 24.33 | 269.27 | 100.68 | 1627.64 | 345.44 |
ADAG Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Adagene Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 8.7% | 0.9% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 8.7% | 0.9% | — | — | — |
| Shares Outstanding | — | $36M | $35M | $35M | $32M | $28M | $35M | $10M |
Peer Comparison
Compare ADAG with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ADAGYou | $210M | -3.8 | — | — | -797.5% | -34835.4% | -55.2% | — | — |
 ZLAB | $2B | -10.7 | — | — | 58.5% | -48.6% | -22.6% | -41.7% | — |
 BCAB | $5M | -0.1 | — | — | 100.0% | -2965.3% | — | — | — |
 IMVT | $7B | -12.1 | — | — | — | — | -64.8% | — | — |
 XNCR | $904M | -9.9 | — | — | 91.6% | -141.4% | -14.0% | -16.3% | — |
 MGTX | $888M | -6.8 | — | — | 94.0% | -130.2% | -368.2% | -241.1% | — |
 RCUS | $2B | -7.2 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 AGEN | $137M | -970.6 | — | — | 29.6% | -18.0% | — | — | — |
 NKTR | $1B | -6.1 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 MRUS | $7B | -26.9 | — | — | 37.2% | -753.0% | -41.4% | -74.6% | — |
 REGN | $64B | 14.8 | 15.3 | 15.6 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
What if you invested $1,000 in ADAG 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in ADAG be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs ADAG Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationADAG vs ZLAB — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Zai Lab Limited.
Compare NowADAG — Frequently Asked Questions
Quick answers to the most common questions about buying ADAG stock.
What is Adagene Inc.'s P/E ratio?
Adagene Inc.'s current P/E ratio is -3.8x. This places it at the 50th percentile of its historical range.
What is Adagene Inc.'s ROE?
Adagene Inc.'s return on equity (ROE) is -55.2%. The historical average is -91.1%.
Is ADAG stock overvalued?
Based on historical data, Adagene Inc. is trading at a P/E of -3.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Adagene Inc.'s profit margins?
Adagene Inc. has -797.5% gross margin and -34835.4% operating margin.